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Abstract
Background: The expression of NDRG1 gene is induced by nickel, a transition metal sharing
similar physical properties to cobalt. Nickel may create hypoxia-like conditions in cells and induce
hypoxia-responsive genes, as does cobalt. Therefore NDRG1 is likely to be another gene induced
by hypoxia. HIF-1 is a transcription factor which has a major role in the regulation of hypoxia-
responsive genes, and thus it could be involved in the transcriptional regulation of NDRG1 gene.
Hypoxia is such a common feature of solid tumours that it is of interest to investigate the
expression of Ndrg1 protein in human cancers.
Results: Hypoxia and its mimetics induce in vitro expression of NDRG1 gene and cause the
accumulation of Ndrg1 protein. Protein levels remain high even after cells revert to normoxia.
Although HIF-1 is involved in the regulation of NDRG1, long term hypoxia induces the gene to some
extent in HIF-1 knock-out cells. In the majority of human tissues studied, Ndrg1 protein is
overexpressed in cancers compared to normal tissues and also reflects tumour hypoxia better than
HIF-1 protein.
Conclusions: Hypoxia is an inducer of the NDRG1 gene, and nickel probably causes the induction
of the gene by interacting with the oxygen sensory pathway. Hypoxic induction of NDRG1 is mostly
dependent on the HIF-1 transcription factor, but HIF-1 independent pathways are also involved in
the regulation of the gene during chronic hypoxia. The determination of Ndrg1 protein levels in
cancers may aid the diagnosis of the disease.
Background
Cancer is a leading cause of death in humans, and current
studies in the clinical area focus on either the early detec-
tion of this disease or on the development of new selective
treatment tools. New tumour markers can provide aid in
cancer diagnosis and create novel treatment
opportunities.
Ndrg1, also named Cap43, Drg 1, RTP and rit42 following
the discovery of its gene (NDRG1) in different laborato-
ries, is a stress responsive protein which shuttles between
cytoplasm and nucleus upon certain insults [1-5]. After its
independent discovery in our lab [1], we worked on the
expression of this gene and the availability of its protein
product in human cells and tissues under different
conditions.
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nickel exposure, we worked on possible ways by which
nickel could change the expression of this gene. Among
the mechanisms investigated were epigenetic changes
(DNA methylation and histone acetylation), signal trans-
duction pathways (tyrosine phosphorylation, adenylate
cyclase cascade, calmodulin, PKC, PI3-K), and ROS-medi-
ated activation. However, none of these mechanisms were
found to be involved in the induction of NDRG1 gene by
nickel compounds [1,6-9].
On the other hand, it was shown that nickel induced the
expressions of several hypoxia-responsive genes including
vascular endothelial growth factor [10], erythropoietin
[11], and glyceraldehyde-3-phosphate dehydrogenase
[12]. Moreover, a well known hypoxia-mimicking agent is
cobalt which is another transition metal adjacent to nickel
in the periodic table. These facts led to the idea that the
NDRG1 could be another hypoxia-responsive gene, and
nickel could induce the expression of this gene creating
hypoxia-like state in cells, as does cobalt. In the present
study, the effects of hypoxia and hypoxia-mimicking
agents on the NDRG1 gene expression have been investi-
gated. Because HIF-1 transcription factor is a major regu-
lator of hypoxia-responsive genes [13,14], the
relationship between NDRG1 gene expression and HIF-1
has also been studied. Here, it is reported that hypoxia is
an inducer of the NDRG1 gene, and that HIF-1 transcrip-
tion factor is involved in the regulation of this gene, but
HIF-1 independent pathways also exist in the induction of
the gene in the case of chronic hypoxia.
The process of tumour expansion is characterized by rapid
growth of cancer cells as the tumour establishes itself in
the host. Accompanying this rapid growth are alterations
in the cancer cell microenvironment, typically caused by
an inability of local vasculature to supply enough oxygen
and nutrients to the rapidly dividing tumour cells. This
makes hypoxia one common feature of solid tumours
[15]. Exploration of Ndrg1 protein expression patterns in
various tissues showed that Ndrg1 protein was overex-
pressed in cancers compared to normal tissues. Because of
its differential expression in cancer tissues and the high
stability of the protein, Ndrg1 is proposed as a useful new
tumour marker.
Results
Hypoxia and its mimetics induce in vitro expression of 
NDRG1 gene
To determine whether hypoxia could induce the transcrip-
tion of the NDRG1 gene, A549 cells were exposed to
hypoxia (0.5% O2) for different time periods. The RNA
transcript of NDRG1 started to appear after 4 hours of
incubation and increased up to 18 hours (Fig. 1A). To
explore if this induction is also translated into protein
response, Ndrg1 protein levels were determined after the
exposure of cells to hypoxia and its mimetics. Figure 1B
shows the accumulation of the protein following the incu-
bation of A549 cells with these agents. To determine
about the longevity of Ndrg1, at the end of hypoxia expo-
sure cells were incubated under normoxic conditions for
different time periods, and the levels of the protein were
assessed. The results of this experiment showed that even
after returning back to normoxia Ndrg1 protein levels
remained elevated for at least 16 hours, indicating the sta-
ble nature of the protein (Fig. 1C). The induction of the
Ndrg1 protein by hypoxia and transition metals has also
been shown in several other cell lines (Fig. 2), confirming
that this induction is a general phenomenon rather than
being a cell-specific one.
The regulation of NDRG1 expression by HIF-1 
transcription factor
HIF-1 is a heterodimeric transcription factor consisting of
HIF-1α and HIF-1β subunits. It is expressed by all cells of
the human body in response to hypoxia and contributes
to the regulation of hypoxia-responsive genes. HIF-1α is
the unique, O2-regulated subunit that determines HIF-1
activity whereas HIF-1β is expressed ubiquitously and is a
common partner of several other proteins. Therefore, the
elimination of HIF-1α expression completely prevents the
formation of HIF-1 protein. To investigate the relation-
ship between HIF-1 transcription factor and the expres-
sion of NDRG1 gene, HIF-1 proficient (HIF-1α+/+) and
deficient (HIF-1α-/-) cells were exploited. Short-term
hypoxia (20 hrs) experiment showed that NDRG1 mRNA
was induced in HIF-1 proficient but not in deficient cells
(Fig. 3A). The transcriptional induction of the gene by
both nickel and cobalt was also dependent upon HIF-1
transcription factor. These results have been confirmed
with the data obtained at the protein level: the same
agents (short-term hypoxia, nickel, and cobalt) caused the
accumulation of Ndrg1 protein in HIF-1 proficient but
not in deficient cells (Fig. 3B).
In another experiment, HIF-1α+/+ and HIF-1α-/-cells were
exposed to long-term hypoxia up to three days, to simu-
late the chronic conditions that cancer cells go through.
The results revealed that hypoxia increased Ndrg1 protein
levels even in HIF-1α-/- cells starting from the second day
of hypoxia (Fig. 3C). However, the level of protein accu-
mulation on the third day was considerably higher in HIF-
1α+/+ cells than in HIF-1α-/- cells. These observations
implied that the Ndrg1 protein induction was not totally
dependent on HIF-1 transcription factor, and that some
other pathways were also involved in the induction of
Ndrg1 protein by long-term hypoxia.Page 2 of 11
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normal and cancerous human tissues
Figure 4 shows a variety of human normal and cancer tis-
sues stained immunohistochemically with anti-Ndrg1
polyclonal antibody. To understand whether elevations of
Ndrg1 protein coincided with the expression of HIF-1
transcription factor, we also stained the tissues with an
antibody to HIF-1α (Fig. 5). In lung, Ndrg1 preferentially
stained malignant cells including both non-small and
small cell types, whereas surrounding normal tissue
remained negative for staining (Fig. 4A,4B). In contrast to
Ndrg1, HIF-1α was present in both normal and lung can-
cer cells at similar levels (Fig. 5A,5B, and Table 1). As
shown in Figure 5B, HIF-1α was present at higher levels in
some cancer cells but not to the extent of Ndrg1 (Fig. 4B).
The induction of NDRG1 gene expression by hypoxia and its mimeticsFigure 1
The induction of NDRG1 gene expression by hypoxia 
and its mimetics. A) A549 cells were exposed to nor-
moxia (20% O2, control) for 20 hours or to hypoxia (0.5% 
O2) for the time periods indicated in the figure. 15 µg of total 
RNA was isolated and subjected to a Northern blot analysis 
as described in 'Methods' section. The blot first hybridized 
with NDRG1 probe (top panel), and then the membrane was 
stripped and rehybridized with actin probe (bottom panel) to 
show loading. B) A549 cells were exposed to 0.5 mM NiCl2 
(Nickel), 200 µM CoCl2 (Cobalt), 200 µM desferrioxamine 
(DFX), or hypoxia (0.5% O2) for 20 hrs. 40 µg of whole cell 
protein extracts were loaded into each lane and subjected to 
Western blot analysis as described in 'Methods' section, using 
antibody against Ndrg1. Bottom panel (actin) shows loading. 
C) A549 cells were first exposed to hypoxia (0.5% O2) for 
20 hrs, then taken out of hypoxic chamber and incubated 
additionally for the time periods indicated under normoxic 
(20% O2) conditions. Western blot analysis with antibody 
against Ndrg1 was carried out in whole cell protein extracts. 
Bottom panel (actin) shows loading.
The confirmation of Ndrg1 protein induction in different cell linesFigure 2
The confirmation of Ndrg1 protein induction in dif-
ferent cell lines. (A) HTE cells were incubated with differ-
ent concentrations of NiCl2 (Ni), hypoxia, and 300 µM of 
CoCl2 (Co) for 20 hrs. (B) HOS and MCF-7, (C) PW and 
DU-145 cells were incubated with 500 µM of NiCl2 (nickel), 
hypoxia, and 300 µM of CoCl2 (cobalt) for 20 hrs. Western 
blot analyses were done as described in 'Methods' section. 
The membranes were first incubated with anti-Ndrg1 anti-
body (top panels), then stripped, and rehybridized with anti-
actin antibody (bottom panels) to show loading.Page 3 of 11
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cells whereas normal brain remained negative for this
staining. Figure 4C shows the normal brain tissue staining
and Figure 4D shows human glioblastoma multiforme.
Ndrg1 preferentially stained the tumour cells adjacent to
the necrotic areas which were supposed to be hypoxic. In
both astrocytomas and hemangioblastomas there was
intense staining for both Ndrg1 and HIF-1α in a number
of different patients. Skin cancer melanoma cells showed
the most intensive staining with Ndrg1 antibody (Fig. 4F),
and a benign skin lesion nevus had very limited Ndrg1
staining (Fig. 4E). In contrast, staining with HIF-1α anti-
body showed little effect in melanoma cells (Fig. 5H).
Ndrg1 protein was generally found at low levels in most
normal tissues with the exception of some higher expres-
sion in the distal and proximal convoluted tubule of the
kidney (Fig 4G, and Table 1). The distal and proximal
convoluted tubules of the kidney also expressed HIF-1α
(Fig. 5C). There was also expression of Ndrg1 protein in
normal colon mucosa and smooth muscle, as well as
some expression in normal breast and prostate (Fig. 4I,4K,
and 4M). However, with the exception of the colon sam-
ples, the expression of Ndrg1 protein in cancer cells of
these tissues was considerably higher (Fig. 4L,4N). In nor-
mal human tissues that showed immune reactivity to
Ndrg1 antibody (such as kidney, prostate, breast, and
colon) staining was emphasized particularly in glandular
structures and tubular epithelia. Table 1 summarizes the
total number of tissues and staining intensities. As seen
from the table, differential expression between normal
and cancer tissues was much more apparent in Ndrg1
than HIF-1α.
Discussion
Experiments conducted in this study provide clear evi-
dence that hypoxia and its mimetics induce the expression
of NDRG1 gene at both the RNA and protein level (Figs.
1, 2, and 3). It is hypothesized that nickel induces this
gene by creating hypoxia-like conditions in cells. Support
for this hypothesis came with the discovery of the first
molecular oxygen sensors in mammalian cells, namely
proline and asparagine hydroxylase enzymes which regu-
late the oxygen-dependent post-translational modifica-
tion of HIF-1α protein and thereby change its stability and
transcriptional activity. Prolyl hydroxylase PHD hydroxy-
lates HIF-1α at residue Pro564 in the presence of oxygen
which creates a signal for pVHL to bind it, causing consec-
utive ubiquitination and proteasomal degradation of HIF-
1α protein [16,17]. Likewise, in the presence of oxygen
asparaginyl hydroxylase enzyme FIH-1 (factor inhibiting
HIF-1) hydroxylates C-TAD domain of HIF-1α which in
turn prevents it binding to coactivator p300/CBP and lim-
its transactivation ability [18-21]. Under hypoxic condi-
tions these modifications of HIF-1α by above mentioned
The role of HIF-1 in the regulation of NDRG1 gene expressionFigu e 3
The role of HIF-1 in the regulation of NDRG1 gene 
expression. A) HIF-1 proficient (HIF-1α+/+) and deficient 
(HIF-1α-/-) cells were exposed to 0.5 mM NiCl2, 300 µM 
CoCl2, and hypoxia (0.5% O2) for 20 hrs. 15 µg of total RNA 
was isolated and subjected to a Northern blot analysis using 
NDRG1 probe (top panel). Ethidium bromide staining was 
used to adjust loading (bottom panel). B) HIF-1α+/+ and HIF-
1α-/- cells were exposed to 0.5 mM NiCl2, 300 µM CoCl2, 
and hypoxia (0.5% O2) for 20 hrs. 40 µg of protein extracts 
were subjected to Western blot analysis using antibody 
against Ndrg1 protein (top panel). Actin bands in the bottom 
panel show loading. C) Cells were first incubated for 24 
hours under normoxic conditions for attachment (Day 0) 
and then exposed to hypoxia for up to three days. Western 
blot analysis with antibody against Ndrg1 was carried out in 
25 µg of whole cell protein extracts (top panel). Actin bands 
in the bottom panel show loading.Page 4 of 11
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responsive genes are promoted [22-24].
The hypoxia-responsive element (HRE) is a specific five
nucleotide-HIF binding-DNA sequence (5'-RCTCG-3')
which is common in all hypoxia-responsive genes
[25,26]. NDRG-1 gene has three HIF-1 binding sites in its
non-coding sequence, one in its promoter and the other
two in the 3' untranslated region [27]. It is known that a
HIF-1 binding site in the 3' region of the erythropoietin
gene regulates the transcription of this hypoxia-responsive
gene [28]. Conceivably, NDRG1 is likely to be regulated
by HIF-1 through the binding sites in its untranslated
sequences.
HIF-1 modifier enzymes, PHD and FIH-1, both have non-
heme iron centres (29), and transition metals nickel and
cobalt can interact with these centres, subsequently inhib-
iting the enzymes (30). By their effects on HIF-1 modify-
ing enzymes, nickel and cobalt have the capacity of
creating constitutive hypoxia-like conditions in cells [31-
33].
Our hypothesis relating nickel, oxygen-sensing, hypoxia,
HIF-1, pVHL, and NDRG1 expression may be elaborated
as follows: when we expose cells to nickel, internalized
nickel inhibits PHD enzyme interacting with its iron cen-
tre. This prevents the hydroxylation of proline residue in
the ODD domain of HIF-1α and subsequent pVHL
binding, rescuing HIF-1α from proteasomal degradation
(Fig. 6, upper part). Rescued and accumulated α subunits
of HIF-1 form stable heterodimers with β subunits and
translocate to the nucleus, and HIF-1αβ heterodimers
bind to hypoxia responsive elements (HRE) of the
NDRG1 gene and promote the transcription of the gene.
Nickel also inhibits the FIH-1 enzyme and subsequent
hydroxylation of C-TAD domain of HIF-1α, and this in
turn results in the recruitment of coactivators of HIF-1 to
the NDRG1 gene regulatory sequences thereby further
stimulating the expression of the gene (Fig. 6, lower part).
However, since the experiments to show the specific
interaction between metals and HIF-1 modifying enzymes
are yet to be executed, this aspect of the hypothesis
remains unproven.
Ndrg1 protein outlasts HIF-1 after hypoxia. Despite being
a major regulator of hypoxia response, HIF-1 transcrip-
tion factor is a very unstable protein which is rapidly
degraded under normoxic conditions; the half-life of HIF-
1α in post-hypoxic cells is less than 5 minutes. On the
other hand our results showed that Ndrg1 protein levels
remain high at least 16 hours after returning to normoxic
conditions (Fig. 1C). Similar results have been reported
by Lachat et al. (34) who showed that it took 48 hours for
Ndrg1 levels to return to pre-anoxic levels after the
cessation of hypoxia. Their experiment carried out in
colon carcinoma cells (SW480) supports our results, indi-
cating that the high stability of Ndrg1 protein is not cell
specific.
Our study of relationship between HIF-1 and NDRG1
expression indicated that the induction of the gene was
primarily dependent on this transcription factor (Fig. 3).
Neither RNA nor the protein product of NDRG1 gene was
Table 1: The presence of Ndrg1 and HIF-1α proteins in various normal and malignant human tissues
TISSUE (n) Ndrg1 HIF-1α
- + ++ +++ - + ++ +++
Normal Lung (30) 24 6 - - 4 11 15 -
Lung Cancer (30) - - 3 27 - 6 21 3
Normal Liver (20) 7 13 - - 2 15 3 -
Liver Cancer (20) - - 4 16 - 11 2 7
Normal Breast (18) 3 13 2 - 1 9 8 -
Breast Cancer (20) - - 6 14 - 4 7 9
Smooth Muscle (30) 12 15 3 - 9 11 10 -
S.M. Cancer (24) - 6 7 11 - 9 12 3
Normal Brain (28) 24 4 - - 18 10 - -
Brain Cancer (36) - - 11 25 - - 15 21
Normal Kidney (15) - 6 8 1 - 5 10 -
Kidney Cancer (22) - - 7 15 - 7 9 6
Normal Skin (20) 14 6 - - 11 9 - -
Melanoma (10) - - - 10 4 6 - -
Tissues were stained immunohistochemically with antibodies against Ndrg1 and HIF-1α as described in 'Methods' section. Each value shown in the 
table is from a single tissue sample from an individual patient. The numbers in parentheses (n) represent the total numbers of tissues stained with 
both antibodies. The expression levels were marked as follows: (-) no staining; (+) weak; (++) moderate; (+++) overexpression.Page 5 of 11
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hypoxia. In the long-term hypoxia experiment we
detected some amount of Ndrg1 protein in HIF-1α-/- cells
starting from the second day, but the levels of protein
accumulation on the second and third days were consid-
erably higher in HIF-1α+/+cells than those in HIF-1α-/-
cells. However, these results indicate that in chronic
hypoxic conditions such as cancer, other factors addi-
Immunohistochemical detection of Ndrg1 protein in human tissuesFigure 4
Immunohistochemical detection of Ndrg1 protein in human tissues. The nature of the tissue is indicated on top of 
each picture. Original magnifications are as follows: A, ×400; B, ×400; C, ×100; D, ×100; E, ×400; F, ×400; G, ×400; H, ×400; I, 
×100; J, ×100; K, ×400; L, ×400; M, 100; N, ×100.Page 6 of 11
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BMC Genetics 2004, 5:27 http://www.biomedcentral.com/1471-2156/5/27tional to HIF-1 could be involved in the regulation of
NDRG1 gene expression. Several HIF-1 independent path-
ways have been described to date as being effective under
hypoxic conditions (35–40).
Our work in several human tissues showed that in the
majority of these organs Ndrg1 protein was differentially
overexpressed in cancers compared to normal tissues (Fig.
4, Table 1). Normal tissue samples of certain organs (lung
and brain) were almost completely free of Ndrg1 expres-
sion, whereas these samples showed HIF-1 protein expres-
sion to some extent. In some cases (especially
glioblastoma of brain) the expression of Ndrg1 coincided
with HIF-1 protein, indicating that induction of HIF-1α
by hypoxia probably resulted in Ndrg1 accumulation in
these cancers. In most of the other cases though, diffuse
and strong Ndrg1 expression did not coincide with HIF-1
protein expression. These differences in the detection of
two proteins may be explained by (i) considerably higher
stability of Ndrg1 protein compared to that of HIF-1, and
(ii) reflection of HIF-1 independent hypoxia response by
Ndrg1. With these features, Ndrg1 has the capacity of
reflecting tumour hypoxia in a broader spectrum than
does HIF-1 and could be considered as a better signature
for hypoxic tumour cells than HIF-1. Therefore, despite
the proposal of HIF-1 as a tumour marker [41], we present
its down-stream product Ndrg1 as a stronger candidate of
cancer marker especially for certain tissues (lung, brain,
and skin).
Several normal tissue samples showed some Ndrg1
expression albeit at lower levels than in cancer samples of
similar tissues. In their comprehensive study, Lachat et al.
(34) showed the expression of Ndrg1 protein in normal
human tissues, reporting also the intensities and sub-cel-
lular localizations of the stainings. We observed similar
staining patterns in several tissues; more emphasized
stainings in the glandular, acinar, ductal, and tubular cells
of normal breast, prostate, colon, and kidney tissues. We
also share the observation that Ndrg1 exist in all three
locations of the cells-cytoplasm, nucleus, and membrane.
But, with the exception of colon mucosa, when we stained
the cancerous tissues of above mentioned organs, the
staining was more intense. However, since the differential
expression of Ndrg1 between normal and cancer tissues of
lung, brain, and skin was much starker (Table 1), we pro-
pose Ndrg1 be initially tried as a marker for these tissues.
For the reasons that are unknown, Ndrg1 was expressed at
lower levels in colon cancer than it was in normal colon.
Similar results have also been reported by others [42].
Immunohistochemical detection of HIF-1α protein in human tissuesFigure 5
Immunohistochemical detection of HIF-1α protein in human tissues. The nature of the tissue is indicated on top of 
each figure. Original magnifications are as follows: A, ×400; B, ×400; C, ×100; D, ×100; E, ×100; F, ×100; G, ×40; H, ×40.Page 7 of 11
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BMC Genetics 2004, 5:27 http://www.biomedcentral.com/1471-2156/5/27This could be due to fact that colon epithelium is a
dynamic structure being continuously renewed. Studies
addressing the mechanism of Ndrg1 down-regulation in
colon cancers will shed more light on the function of
Ndrg1 protein and its relation to cancer development.
Another common finding between our study and Lachat
et al's (34) is no expression of Ndrg1 in normal brain and
lung epithelium. Lachat et al. (34) showed at the
transcriptional level that normal brain and lung express
NDRG1, in fact these and many other tissues expressing
NDRG1 mRNA did not contain detectable levels of the
protein product of this gene. This could be due to degra-
dation of the mRNA under normal conditions. Stabilizing
the mRNAs of hypoxia-responsive genes is one way cells
promote the expression of these genes under hypoxic con-
ditions (38, 39). More studies are needed to resolve how
Ndrg1 levels are managed in normal cells, during hypoxia,
and as well as in cancer cells.
Masuda et al. [40] report the down-regulation of NDRG1
gene by VHL tumour suppressor protein (pVHL). They
state that no hypoxia-responsive element exists on the 5'
flanking sequence of the gene and thus underplay the role
of HIF-1 in the regulation of NDRG1. As mentioned pre-
viously, NDRG-1 gene has three HIF-1 binding sites, one
in its promoter and two in the 3' untranslated region.
Therefore, the down-regulation of NDRG1 gene by pVHL
is likely to be mediated through the HIF-1 pathway. The
observation of NDRG1 being down-regulated by a major
tumour suppressor further supports our observation that
it is up-regulated in several cancer tissues and could be
used as a marker.
Hypoxia-responsive pathway (HRP) allows tumour cells
to overcome harsh microenvironment conditions associ-
ated with tumour growth. The protein products of
induced by this pathway (e.g. EPO, VEGF, several glyco-
lytic enzymes) allow clones of tumour cells to gain growth
advantage under unfavourable conditions, and this con-
cept is pivotal in switching to a more malignant pheno-
type. Although the exact functions of Ndrg1 are still
unknown, as another effector of HRP, it is also likely to
help tumour cells establish themselves. Therefore, the use
of drugs that specifically disrupt the functions of Ndrg1
protein may provide new cancer therapies. It is thus of
interest to investigate the effects of the elimination of this
protein on the cancer cell survival and proliferation. How-
ever, first Ndrg1 expression in normal hypoxic tissue
(such as infarct tissues) should be determined to show the
cancer specificity of the protein. Second, the potential side
effects of its elimination should be assessed since several
normal tissues express Ndrg1 ubiquitously.
Hypoxia is also an important determinant for the success
of chemotherapy and radiotherapy [43]. Masuda et al.
[40] even argue that Ndrg1 could be involved in limiting
sensitivity to anti-cancer drugs. However hypoxia is an
equally likely limiting factor in anti-cancer therapy, and
Ndrg1 may be simply the signature of the hypoxic state.
Conclusions
Hypoxia induces the NDRG1 gene, and nickel probably
causes the induction of the gene by interacting with the
oxygen sensory pathway. Hypoxic induction of NDRG1 is
mostly dependent on HIF-1 transcription factor. How-
ever, regulation of the gene in long term hypoxia involves
some other HIF-1 independent pathways.
Ndrg1 protein was overexpressed in the majority of can-
cers studied here. With the exception of colon cancer,
staining with Ndrg1 antibody distinguished between nor-
mal and tumour cells in most cancerous tissues. The
mechanism of this overexpression is related to the
hypoxic state of cancer cells. Ndrg1 protein is a better indi-
cator of tumour hypoxia than HIF-1 in immunohisto-
chemical analyses. This is probably due to the stable
nature of the Ndrg1 protein compared to the very unstable
HIF-1 protein, and also to capacity of Ndrg1 in reflecting
HIF-1 independent hypoxia response. Therefore, the
The illustration of the hypothetical mechanism by which nicke  and cobalt upr gulate the expr ssio  of the NDRG1 geneFigure 6
The illustration of the hypothetical mechanism by which 
nickel and cobalt upregulate the expression of the NDRG1 
genePage 8 of 11
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provide a more useful tool for cancer diagnosis. Even
though the exact functions of Ndrg1 protein are still
unknown, as another effector in hypoxia-response, it can
help cancer cells to survive and grow under unfavourable
conditions. Therefore, it may also be possible to direct
therapy towards Ndrg1 protein using drugs that specifi-
cally disrupt the functions of this protein.
Methods
Cell lines and culture conditions
Human lung cancer cell line A549 (CCL185), human
osteosarcoma cell line HOS (CRL 1543), human mam-
mary carcinoma cell line MCF-7 (HTB 22), and human
prostate cancer cell line DU-145 (HTB 81) were purchased
from American Type Culture Collection (Rockville, MD,
USA). Human trachea epithelium (HTE) cells, HIF-1α+/+,
and HIF-1α-/- fibroblasts were gifts from Dr. Konstantin
Salnikow of NYU. The production of HIF-1α+/+ and HIF-
1α-/- fibroblasts was described elsewhere [44]. PW cells
were a gift from Dr. Qunwei Zhang of NYU.
The cell lines were maintained at 37°C as monolayers in
a humidified atmosphere containing 5% CO2. Cells were
passaged by trypsinization when they reached 70–80%
confluence. A549 cells were grown in Ham's F-12K nutri-
ent mixture (Kaighn's modification) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin [equivalent to 100 units (U)/ml and 100 µg/ml,
respectively]. MCF-7, PW, HIF-1α+/+, and HIF-1α-/- cells
were maintained in DMEM (Dulbecco's modified Eagle's
medium) with the same supplements. HOS and HTE cells
were grown in α-MEM (α-minimal essential medium)
additionally supplemented with 2 mM L-glutamine. For
Northern and Western blot experiments, 5 × 105 cells in
10 ml of media were plated in each of 10-cm dishes
(Corning Inc, Corning, NY). Cell numbers were deter-
mined using the ZM Coulter Counter (Coulter Electron-
ics, England). To render cells hypoxic, dishes were placed
in an incubator chamber flushed with 95% N2 and 5%
CO2. This resulted in approximately 0.1–0.5% O2 after
several hours. After 20 hours, cells were released from
hypoxia and quickly scraped in ice-cold phosphate-buff-
ered saline (PBS), and analyses were performed as
described below.
Northern blot analysis
Total RNA was extracted from cells immediately after
exposures by using TRIzol reagent (Gibco-BRL) according
to instructions of the manufacturer. 15 µg of RNA/lane
was separated by electrophoresis in 1.0% agarose-formal-
dehyde gels and then transferred to nitrocellulose
membranes (BA-85; Scleicher & Schuell). NDRG1 and
actin probes were labelled with [α-32P]dCTP by using a
randomly primed-DNA labelling kit (Promega). Cloning
of NDRG1 gene was as described previously [1]. The blot
first hybridized with NDRG1 probe, and then the mem-
brane was stripped and rehybridized with actin probe to
show loading. The bands were visualized by exposing X-
ray films (Eastman Kodak Co, NY, USA) to hybridized
membranes.
Western blot analysis
Cells were lysed, and proteins were harvested in 125 µl of
TNES buffer [50 mM Tris-HCl (pH: 7.5), 2 mM EDTA, 100
mM NaCl, 1 mM sodium orthovanadate (Na3VO4), 10
mM sodium fluoride, and 1% NP40] containing protease
inhibitors (PMSF 1 mM, aprotinin 1 µg/ml, leupeptin 5
µg/ml, and chymostatin 2 µg/ml). 40 µg or 25 µg of pro-
tein was loaded into each lane of a 10% SDS-PAGE gel
and separated by electrophoresis. Proteins were then
transferred to PVDF membranes (Roche Diagnostics Co,
IN, USA), and the membranes were first incubated with
rabbit anti-Ndrg1 polyclonal antibody at the dilution of
1:1000 in 5% non-fat dry milk for one hour at room tem-
perature. The antibody production is described elsewhere
[3]. After washing four times for 15 min each with TBS
buffer, the membranes were incubated with a second anti-
rabbit peroxidase-conjugated antibody (Santa Cruz, CA,
USA) at the dilution of 1:104 in 5% milk for one hour at
room temperature. At the end the membranes were
treated with chemiluminiscent substrate ECL (Amersham
Pharmacia Biotech, UK) for 1 min at room temperature,
and Biomax MR-1 films (Eastman Kodak Co, NY, USA)
were exposed to the membranes. The molecular weight of
Ndrg1 was determined using prestained molecular weight
markers (Invitrogen Life Technologies, CA, USA).
Tissue staining
For in vivo detection of Ndrg1 protein in human cancer
and normal tissues, immunohistochemical (IHC) stain-
ing was exploited, using a rabbit polyclonal antibody
against a 30-aminoacid-sequence at the C-terminal end of
the Ndrg1 protein [3]. Tumour and normal tissue sections
were obtained from the tumour registry of the Cancer
Institute of New York University Medical School. The tis-
sues were embedded in paraffin wax. Five-micron sections
were cut and baked at 60°C for 30 minutes. After cooling,
the sections were deparaffinized and hydrated through
the following series: 3 × 5 minutes xylene, 3 × 5 minutes
100% Etoh (ethyl alcohol), 3 × 5 minutes 95% Etoh. The
slides were then rinsed gently with distilled water and
stained with hematoxylin-eosin for histopathological
diagnosis. For antigen retrieval, the slides were heated in
1 mM EDTA buffer (pH: 8.0) in a microwave oven for 10
min, and then endogenous peroxide was blocked with
methanol containing 0.35% H2O2 for a further 30 min.
After incubation with the antibody against Ndrg1 protein
overnight, the slides were processed with a second anti-
rabbit peroxidase-conjugated antibody (Santa Cruz, CA,Page 9 of 11
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using Avidin-Biotin horseradish peroxidase complex and
3,3-diaminobenzidine (DAB) as the chromogen. Negative
controls were performed using nonimmune serum
instead of primary antibodies.
Immunohistochemical detection of HIF-1α protein was
achieved by using Catalyzed Signal Amplification System
(DAKO Corp., Carpinteria, CA) which is based on strepta-
vidin-biotin-horseradish peroxidase complex formation.
Antigen retrieval was done by 10 mM sodium citrate
buffer (pH 6.0). The specimens were incubated overnight
at +4°C with monoclonal anti-HIF-1α antibody (Clone
MAb H1α 67, #NB 100–123; Novus Biologicals, Littleton,
CO) in a dilution of 1:1000. After the amplification of the
signal according to manufacturer's instructions, the slides
stained with chromogen DAB, counter-stained with
hematoxylin, dehydrated, and then mounted.
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